Literature DB >> 21288262

Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population.

Vassilis Ladis1, Giorgos Chouliaras, Vasilios Berdoukas, Antonia Chatziliami, Christina Fragodimitri, Fotis Karabatsos, Jacqueline Youssef, Antonis Kattamis, Markissia Karagiorga-Lagana.   

Abstract

BACKGROUND: With transfusions and chelation therapy, the prognosis for transfusion-dependent beta thalassaemia has changed from being fatal in early childhood to a chronic disorder with prolonged survival. DESIGN AND METHODS: In this historical prospective study, we present survival, causes of death and mortality ratios compared to the general population in 1044 Greek patients with transfusion-dependent beta thalassaemia.
RESULTS: At the age of 50years, the overall survival was 65.0%, while the cardiac death-free survival was 77%. Birth cohort had a significant effect on survival (P<0.001) with a negative trend towards past decades. The standardised mortality ratio (standardised for sex and ages 20-40years) compared to the general population improved significantly from 28.9 in 1990-1999 to 13.5 in 2000-2008, while the standardised cardiac mortality ratio reduced from 322.9 to 106.6, respectively.
CONCLUSIONS: Survival in thalassaemia has dramatically improved over the last twenty years but mortality remains significantly increased, compared to the general population.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 21288262     DOI: 10.1111/j.1600-0609.2011.01582.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

Review 1.  Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.

Authors:  John Porter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort.

Authors:  Venée N Tubman; Ellen B Fung; Maria Vogiatzi; Alexis A Thompson; Zora R Rogers; Ellis J Neufeld; Janet L Kwiatkowski
Journal:  J Pediatr Hematol Oncol       Date:  2015-04       Impact factor: 1.289

3.  Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent β-thalassaemia in the United Kingdom: A mixed methods observational study.

Authors:  Farrukh Shah; Paul Telfer; Mark Velangi; Shivan Pancham; Robert Wynn; Sally Pollard; Elizabeth Chalmers; Jonathan Kell; Angela M Carter; Joe Hickey; Clark Paramore; Minesh Jobanputra; Kate Ryan
Journal:  EJHaem       Date:  2021-09-08

4.  Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.

Authors:  Farid Boulad; Aurelio Maggio; Xiuyan Wang; Paolo Moi; Santina Acuto; Friederike Kogel; Chayamon Takpradit; Susan Prockop; Jorge Mansilla-Soto; Annalisa Cabriolu; Ashlesha Odak; Jinrong Qu; Keyur Thummar; Fang Du; Lingbo Shen; Simona Raso; Rita Barone; Rosario Di Maggio; Lorella Pitrolo; Antonino Giambona; Maura Mingoia; John K Everett; Pascha Hokama; Aoife M Roche; Vito Adrian Cantu; Hriju Adhikari; Shantan Reddy; Eric Bouhassira; Narla Mohandas; Frederic D Bushman; Isabelle Rivière; Michel Sadelain
Journal:  Nat Med       Date:  2022-01-03       Impact factor: 87.241

5.  A genetic score for the prediction of beta-thalassemia severity.

Authors:  Fabrice Danjou; Marcella Francavilla; Franco Anni; Stefania Satta; Franca-Rosa Demartis; Lucia Perseu; Matteo Manca; Maria Carla Sollaino; Laura Manunza; Elisabetta Mereu; Giuseppe Marceddu; Serge Pissard; Philippe Joly; Isabelle Thuret; Raffaella Origa; Joseph Borg; Gian Luca Forni; Antonio Piga; Maria Eliana Lai; Catherine Badens; Paolo Moi; Renzo Galanello
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

Review 6.  Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects.

Authors:  Jorge Mansilla-Soto; Isabelle Riviere; Farid Boulad; Michel Sadelain
Journal:  Hum Gene Ther       Date:  2016-04       Impact factor: 5.695

7.  International survey of T2* cardiovascular magnetic resonance in β-thalassemia major.

Authors:  John-Paul Carpenter; Michael Roughton; Dudley J Pennell
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

8.  The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.

Authors:  Emmanouil Petrou; Sophie Mavrogeni; Vasiliki Karali; Genovefa Kolovou; Marie-Christine Kyrtsonis; Petros P Sfikakis; Panayiotis Panayiotidis
Journal:  Rev Bras Hematol Hemoter       Date:  2015-05-19

9.  Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.

Authors:  Anuraag R Kansal; Odette S Reifsnider; Sarah B Brand; Neil Hawkins; Anna Coughlan; Shujun Li; Lael Cragin; Clark Paramore; Andrew C Dietz; J Jaime Caro
Journal:  J Mark Access Health Policy       Date:  2021-06-07

10.  Treating thalassemia major-related iron overload: the role of deferiprone.

Authors:  Vasilios Berdoukas; Kallistheni Farmaki; Susan Carson; John Wood; Thomas Coates
Journal:  J Blood Med       Date:  2012-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.